期刊
STAR PROTOCOLS
卷 2, 期 1, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.xpro.2021.100334
关键词
-
资金
- UMC Utrecht Clinical Fellowship
- Netherlands Heart Institute Fellowship
- CVON-Dosis young talent grant
- Stanford Child Health Research Institute Post-doctoral Fellowship
- NIH NRSA Postdoctoral Fellowship [5F32HL142205, R01 HL145676, R01 HL146690, P01 HL141084]
- NIH [OD004411, HL099776, LM012179]
- Netherlands Heart Foundation [CVON-Dosis 2014- 40]
- Netherlands Organization for Sciences (NWO) -ZonMW [VICI 91818602]
- Dutch Research Council (NWO) VENI [016.176.136]
- Foundation Leducq (Cure-PLaN)
- Joan and Sanford I. Weill Scholar Fund
- PLN Foundation
- Horizon2020 ERC-2016-COG EVICARE
- UCL Hospitals NIHR Biomedical Research Centre
- Horizon 2020 BRAV3 [116002016]
- ZonMw-TAS program [725229]
- [SC1-BHC-07-2019]
This study introduces a cost-effective strategy for expanding high-purity hiPSC-CMs at a large scale, maintaining functionality and enabling a variety of downstream applications.
Since the discovery of human induced pluripotent stem cells (hiPSCs), numerous strategies have been established to efficiently derive cardiomyocytes from hiPSCs (hiPSC-CMs). Here, we describe a cost-effective strategy for the subsequent massive expansion (>250-fold) of high-purity hiPSC-CMs relying on two aspects: removal of cell-cell contacts and small-molecule inhibition with CHIR99021. The protocol maintains CM functionality, allows cryopreservation, and the cells can be used in downstream assays such as disease modeling, drug and toxicity screening, and cell therapy.For complete details on the use and execution of this protocol, please refer to Buikema (2020).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据